Long Grove intros generic Hemabate
Generic hemabate is indicated for the treatment of postpartum hemorrhage due to uterine atony.
Long Grove Pharmaceuticals is launching carboprost tromethamine injection, which is the generic of Pfizer’s Hemabate.
The medication, which is indicated for the treatment of postpartum hemorrhage due to uterine atony, is available in a vial presentation.
[Read more: Long Grove Pharmaceuticals launches generic Kenalog-40]
“The launch of carboprost tromethamine injection continues Long Grove Pharmaceuticals’ commitment to rapid development of differentiated generics,” said Dan Robins, president and CEO of Long Grove. “Our team has deep experience navigating the complex regulatory landscape and supply chain. We remain focused on bringing even more products like this to market as our portfolio expands.”